175250 — Icure Pharmaceutical Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩76bn
- KR₩144bn
- KR₩57bn
- 25
- 30
- 63
- 29
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Interim Report | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 36,175 | 13,718 | 24,417 | 53,786 | 8,558 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 15,075 | 17,350 | 17,144 | 16,221 | 8,986 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 68,897 | 43,726 | 58,796 | 80,705 | 31,812 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 97,306 | 107,813 | 101,312 | 96,943 | 93,526 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 215,798 | 195,149 | 215,448 | 224,121 | 166,137 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 36,787 | 34,110 | 54,818 | 109,981 | 95,439 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 118,267 | 82,995 | 119,693 | 134,450 | 107,900 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 97,531 | 112,154 | 95,755 | 89,671 | 58,238 |
Total Liabilities & Shareholders' Equity | 215,798 | 195,149 | 215,448 | 224,121 | 166,137 |
Total Common Shares Outstanding |